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http://www.virologyj.com/content/9/1/204RESEARCH Open AccessMultiple linear epitopes (B-cell, CTL and Th) of
JEV expressed in recombinant MVA as multiple
epitope vaccine induces a protective immune
response
Fengjuan Wang1†, Xiuli Feng1†, Qisheng Zheng2, Hongyan Hou3, Ruibing Cao1*, Bin Zhou1, Qingtao Liu4,
Xiaodong Liu1, Ran Pang1, Jin Zhao1, Wenlei Deng1 and Puyan Chen1Abstract
Epitope-based vaccination might play an important role in the protective immunity against Japanese encephalitis
virus (JEV) infection. The purpose of the study is to evaluate the immune characteristics of recombinant MVA
carrying multi-epitope gene of JEV (rMVA-mep). The synthetic gene containing critical epitopes (B-cell, CTL and Th)
of JEV was cloned into the eukaryotic expression vector pGEM-K1L, and the rMVA-mep was prepared. BALB/c mice
were immunized with different dosages of purified rMVA-mep and the immune responses were determined in the
form of protective response against JEV, antibodies titers (IgG1 and IgG2a), spleen cell lymphocyte proliferation, and
the levels of interferon-γ and interleukin-4 cytokines. The results showed that live rMVA-mep elicited strongly
immune responses in dose-dependent manner, and the highest level of immune responses was observed from the
groups immunized with 107 TCID50 rMVA-mep among the experimental three concentrations. There were almost
no difference of cytokines and neutralizing antibody titers among 107 TCID50 rMVA-mep, recombinant ED3 and
inactivated JEV vaccine. It was noteworthy that rMVA-mep vaccination potentiates the Th1 and Th2-type immune
responses in dose-dependent manner, and was sufficient to protect the mice survival against lethal JEV challenge.
These findings demonstrated that rMVA-mep can produce adequate humoral and cellular immune responses, and
protection in mice, which suggested that rMVA-mep might be an attractive candidate vaccine for preventing JEV
infection.
Keywords: Japanese encephalitis virus, rMVA-mep, Immune response, Protection responseIntroduction
The Japanese encephalitis virus (JEV), which belongs to
the family Flaviviridae, infects the human central ner-
vous system [1,2]. The virus has a zoonotic transmission
cycle between birds and mosquitoes, in which swine
serves as an intermediate amplifier hosts and JEV can
spread from swine to humans via mosquito bites [3-5].
Thus the vaccination of swine against JEV should con-
tribute to minimize the occurrence of JE epidemics in
humans [6].* Correspondence: crb@njau.edu.cn
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reproduction in any medium, provided the orBoth inactivated and live-attenuated vaccines have
been widely used in many Asian countries. Inactivated
mouse brain vaccines are considered first generated,
inactivated cell culture vaccines and live SA14-14-2 are
considered second generation vaccines against JEV [7],
which play vital roles on effectively decreased the mor-
bidity of Japanese encephalitis. During the vaccination
with both inactivated and live-attenuated JEV vaccines,
there are various disadvantageous conditions, including
poor availability, high production costs, poor long-term
immunity, and the possibility of allergic reactions [8].
These problems may be solved by using epitope-based
vaccines containing selected protective epitopes, ap-
propriately presented, which are capable of stimulating
effective B cell, T cell, and cytotoxic immune responsestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[9].
Judging from animal experiments, the protective im-
mune response against JEV infection arises via both
humoral and cellular immunity. Passive immunization
with monoclonal antibodies specific for the JEV E protein
has been shown to protect animals from lethal JEV chal-
lenge [10,11] and the adoptive transfer of JEV-specific
cytotoxic T lymphocytes (CTLs), which confer protection
against lethal challenge in mice [12]. Likewise, the enve-
lope (E) protein of JEV was reported to be a strong
immunogen for the production of neutralizing antibodies
and CTLs [13]. Many vital epitopes identified in the JEV
E protein [14-16] are effective in inducing protective
immunity against JEV. Moreover, it has been reported
that the design and delivery of epitope-based vaccines
have the potential to be a novel vaccine against JEV
[17-19].
In recent years, modified vaccinia virus Ankara has
showed great promise as vectors for recombinant vac-
cine development [20-24]. Despite its replication defi-
ciency in human and most mammalian cells, MVA
provides high-level gene expression and has been proven
to be immunogenic when delivering heterologous anti-
gens in animals and humans [25-27]. MVA vector vac-
cines induce significant levels of humoral and cellular
immune responses to vaccine antigens and were found
to be less affected by preexisting vaccinia virus-specific
immunity when compared to replication-competent vac-
cinia virus vectors [28]. In this study, we first constructed
the recombinant MVA by synthesizing multi-epitope
gene from JEV envelope protein, which combined six
B-cell epitopes (amino acid residues 75–92, 149–163,
258–285, 356–362, 373–399 and 397–403) and a CTL
epitope (amino acid residues 60–68) and a Th epitope
(amino acid residues 436–445) [29], and evaluated the
abilities to induce immune responses in mice and pro-
tective efficacy against JEV challenge.Materials and methods
Cells and mice
Baby hamster kidney (BHK-21) cell (ATCC CCL-10) and
rabbit kidney cell (RK-13) cell (ATCC CCL-37) growed
in Dubach’s modified Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS), 100 μg/mL of streptomycin, and 100 μg/mL of
penicillin.
Female BALB/c mice (4–6 weeks old) were purchased
from the Experimental Animal Center of Nanjing Med-
ical University (Nanjing, China). All animal experiments
were conducted according to the guidelines approved by
the Animal Ethical and Experimental Committee of
Nanjing Agriculture University.Viruses and vaccination control
The SA14 strain of JEV, which maintained in our labora-
tory, was propagated in BHK-21 for the plaque reduction
neutralization test (PRNT) and challenge test. The
viral titers of the supernatants were approximately
6.3 × 107pfu.
MVA (582nd CEF passage), which maintained in our
laboratory, was propagated in BHK-21 and its viral titers
of the supernatants were approximately 1.0 × 108 pfu.
Recombinant proteins MEP and EDIII(which were
used as vaccination control)were expressed in E. coli
BL21 as previous reported [30], and purified on Ni-
affinity chromatography column (Amersham Bioscience
HiTrap chelating HP 5mL× 1column) according to the
manufacturer’s instructions.
The inactivated JEV vaccine (SA14-14-2 strain,
2.0 × 107pfu) was obtained from ZHONGMU BIO-
INDUSTRY CO., LTD.
Preparation of rMVA-mep
Construction of the rMVA-mep
In this paper, according to the previously report [29], the
multiple-epitope fragment from the E protein of JEV
(SA14-14-2 strain), named MEP (eight epitopes), was
designed by arranging the eight epitopes in the order of
amino acids (75–92)–(149–163)–(258–285)–(356–362)–
(373–399)–(397–403)–(60–68)–(436–445). The amino
acid sequence and the nucleotide sequence of MEP are
shown in Figure 1A. To minimize interference between
adjacent epitopes, each was separated from its neighbor-
ing epitope by a glycine and a serine codon [29]. The
multiple-epitope gene was chemically synthesized by
Invitrogen Biotechnology Co. Ltd. (Shanghai, China) and
cloned into the transfer vector pGEM-K1L plasmid and
named pGEM-K1L-mep (Figure 1B).
The MVA recombinants were produced according to
the manufacturer’s instructions [31] on BHK-21 cells,
named rMVA-mep-BHK-21. Simple, the rMVA-mep-
BHK-21, which included rMVA-mep and wild MVA,
was purified by serially infecting RK-13 cells, which was
called rMVA-mep-RK-13. The rMVA-mep-RK-13 with
k1l gene but no MVA was used to transfect BHK-21
cells, in which k1l was removed by intra-genomic hom-
ologous recombination. The purified recombinant MVA
containing multiple-epitope gene was called rMVA-mep,
which was determined by the tissue culture infectious
dose 50 (TCID50) methods.
Identification of rMVA-mep by PCR
To identify that the rMVA-mep contains targeted gene
MEP, the genome of RK-13 cells infected with recombin-
ant viruses were prepared, and PCR was used with the
specific primers of the targeted gene MEP, and specific
gene of wild MVA. Also, the genome of BHK-21 cells
Figure 1 Construction of the rMVA-mep. A. Design and construction of the multi-epitope peptide (MEP). The MEP was constructed from six
B-cell epitopes and two T-cell epitopes, with a glycine and a serine (GS) as a spacer between epitopes. The amino acid sequences of the epitopes
were obtained from the envelope protein of the JEV (AF315119) [29]. B. The construction of the rMVA-mep. pGEM-K1L-mep contains the multi-
epitope peptide (MEP).
Table 1 The primers of Identification of rMVA-mep by
PCR
Gene Primer (from 5’ to 3’)
Mep Forward primer: ctcgagatgccgaccaccggcgaagcgca
Reverse primer:
catatgatttttataaaaatttaaaacacctgatgcaccgcacggccgatgctag
K1l Forward primer: gaatgcacatacataagtaccggcatctctagca
Reverse primer: caccagcgtctacatgacgagcttccgagtt
MVA (wild) Forward primer: acataagtaccggcatctctagcacacagc
Reverse primer: ttcgccggtggtcggcatctcgagagctac
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tect the host range gene k1l and MEP by PCR method.
These primers used were shown in Table 1.
Identification of expressed proteins of MEP
Western blot was performed as described previously
[29]. The lysates of BHK-21 cells infected with or with-
out rMVA-mep were separated by 15% SDS-PAGE, in
which non-infected BHK-21 cells was used as a negative
control. The expressions of MEP proteins were identified
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West-Blotting analysis.
Mouse immunization
Mice were randomly divided into eight experimental
groups (fifteen mice each group) and were immunized
intraperitoneally (i.p.) on weeks 0, 2 and 4, respectively.
The Group 1, Group 2 and Group 3 were given the 106
TCID50/0.1mL, 10
7 TCID50/0.1mL and 10
8TCID50/0.1mL
rMVA-mep, respectively. Vaccine group mice were each
given 0.1ml of JEV (SA14-14-2 strain, 2x106pfu). Also, the
recombinant protein immunization groups were given
purified 50μg MEP and 50μg EDIII in complete Freund’s
adjuvant (CFA) for the first immunizations, in incomplete
Freund’s adjuvant (IFA) for the second and the third
immunizations. In addition, mice immunized with 0.1mL
MVA (2x106pfu) or 0.1mL PBS was used as negative con-
trols (Table 2), respectivley. One week after the final
immunization, three mice from each group were sacri-
ficed, and their spleens removed aseptically for in vitro
lymphocyte proliferation assay. Also, on 14th day after the
third immunization, mice were challenged by i.p. injec-
tion of a lethal dose of 5 × 106 pfu of the JEV (SA14
strain) and the survival of the mice was monitored daily
up to 15 days post-challenge. The animal groups and
immunization doses were described in Table 2, and
immunization schedule was shown in Figure 2.
Antibody assays
The sera were collected at 14, 28 and 42 days after
immunization to perform the antibody assay by ELISA.
Simply, the purified multi-epitope protein (rMEP) was
coated in 96-well plates (1μg/mL) overnight at 4°C. After
blocking, the coated plates were incubated with mouse
serum in a sequential dilution of 1:50, 1:100, 1:200,
1:400, 1:800, 1:1600, 1:3200 and 1:6400 for 1.5 h at 37°C.
And then, 50μL of a 1:1000 dilution of HRP- conjugated
goat anti-mouse IgG, and a 1:2000 dilution of IgG1 and
IgG2a were incubated for 45min at 37°C. After extensive
washing, tetramethyl benzidine (TMB) substrate was
added for 10 minutes at room temperature, and theTable 2 The diagram of mouse immunization
Groups Priming
rMVA-mep 105TCID50 10
6 TCID50/0.1 m
106 TCID50 10
7 TCID50/0.1 m
107 TCID50 10
8 TCID50/0.1 m
Inactivated JEV vaccine 0.1 mL (2x106pfu
EDIII 50 μg CFA
rMEP 50 μg CFA
PBS 0.1 mL
Wild MVA 0.1 mL(2x106pfu)
CFA, complete Freund’s adjuvant; IFA, incomplete Freund’s adjuvant.reaction was stopped with 2M H2SO4, and absorbance
was read at 450 nm. The titer was expressed as the high-
est serum dilution giving an absorbance > 0.2. The back-
ground value was 0.061, and 0.2 was used as cut-off.
Each serum titration was assayed in triplicates.
Estimation of IFN-γ and IL-4 by ELISA
At 7th day after the final immunization, the sera were
collected from all experiment groups to measure the
productions of IL-4 and IFN-γ using commercially mice
cytokine ELISA kits (RD, USA), according to the manu-
facturer’s instructions.
Lymphocyte proliferation assay
One week after the final immunization, three mice of
each group were killed, and splenocyte were prepared,
and were incubated with 10μg/mL rMEP protein in
96-well flat-bottomed microtiter plates (100μL/well,
2 × 106cells/mL in RPMI 1640 medium with 10% FBS).
After incubation for 72 h, a final concentration of
20μg/mL MTT (Sigma) was added to each well for 4-h
incubation. The medium was removed, and 100μL of
DMSO was added into each well [32]. The light absorb-
ance was measured at 570 nm to analyze cell viability
expressed as the value of the A570 of cells from immu-
nized mice vs. the control samples. All the data were
statistically analyzed with SPSS software.
Plaque reduction neutralization assay (PRNT)
Neutralization antibodies elicited in immunized mice
were valuated by PRNT as described previously [33].
Mouse serum was heat inactivated at 56°C for 30 min.
Twofold serial dilutions of murine sera starting at 1:5
were tested, and then incubated with 100 pfu of JEV
(virulent SA-14 strain) at 37°C for 1 h. The virus titers
were then determined by plaque formation on BHK-
21cell monolayers [34,35]. Percentage neutralization was
calculated from the number of plaques obtained in the
presence and the absence of the serum. The reciprocal
of the highest serum dilution giving at least 50%Boost 1 Boost 2
L 106 TCID50/0.1 mL 10
6 TCID50/0.1 mL
L 107 TCID50/0.1 mL 10
7 TCID50/0.1 mL
L 108 TCID50/0.1 mL 10
8 TCID50/0.1mL
) 0.1 mL(2x106pfu) 0.1 mL(2x106pfu)
50 μg IFA 50 μg IFA
50 μg IFA 50 μg IFA
0.1 mL 0.1 mL
0.1 mL(2x106pfu) 0.1 mL(2x106pfu)
Figure 2 Vaccination schedule and viral challenge period of in vivo experiment. Mice were given a first followed by a second
immunization and third immunization. The sera samples were collected at 14, 28 and 42 days after immunization. The immunized mice were
challenged intraperitoneally with a lethal dose of 5 × 106 pfu of the JEV (SA14 strain). The health of each mouse was assessed twice daily.
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titer.
Statistical analysis
The data were recorded as mean ± standard deviation
(SD). Biochemical and physiological parameters were
analyzed statistically using one-way analysis of variance
(ANOVA) followed by Dunnet-t-test using SPSS statis-
tical software to evaluate variations between groups. A
value of P < 0.05 was considered to be statistically
significant.
Results
Generation of the recombinant virus (rMVA-mep) and
purification
Recombinant viruses carrying wild MVA and host range
gene k1l were selected by alternately infecting RK-13
cells and BHK-21cells. The first generation of purified
viruses included targeted gene MEP (437bp), specific
gene of wild MVA (nearly 700bp) and K1l gene (1332bp)
(Figure 3A, lane 4: RK-13-1). To contract with the first
generation, the concentration of wild MVA of the fourthFigure 3 Identification of rMVA-mep. (A, B, C) Identification of rMVA-me
Lane 1, 2, 3, 4: infected cell focus RK-13-6, RK-13-4, RK-13-3, and RK-13-1, re
RK-13-6(k1l gene), RK-13-6(MEP gene), and RK-6(no wild MVA), respectively.
BHK-21-4, BHK-21-2, and BHK-21-1, respectively. M: DL2000 marker. (D) Wes
protein marker; lane 1: Western blot of purified rMEP in E. coli. Lane 2: Wes
on BHK-21 cells). Lane 3: Western blot of purified rMVA-mep infected BHK-generation, RK-13-4 (Figure 3A, lane 2), was obviously
lower. There was no wild MVA in the last generation
(RK-13-6, Figure 3A, lane 1 and Figure 3B, lane 8),
and only the targeted recombinant viruses carrying
host range gene k1l (Figure 3B, lane 6) and targeted
gene MEP (Figure 3B, lane 7) were presented. Under
nonselective growth conditions, k1l was removed by intra-
genomic homologous recombination when the recom-
binant viruses (RK-13-6) were reinfected into BHK-21 cells
(Figure 3C). K1l could not be found in the six generation
on BHK-21 cells (Figure 3C, lane 10), but not in the
fourth, second and first generation (Figure 3C, lane11:
BHK-21-4; lane12: BHK-21-2; lane13: BHK-21-1). These
results showed that recombinant virus has been purified.
Western Blotting of rMVA-mep
The rMEP was highly expressed in E. coli, and purified
with the expected 17.9 kDa protein verified by Western
blotting analysis (Figure 3D, lane 1). Moreover, it was
observed that the MEP of JEV was stably expressed in
BHK-21 cells after rMVA-mep infection, which were
proved by Western blotting analysis with the sixthp by PCR using primers targeted to MEP, to k1l and to MVA gene. (A)
spectively. M: DL2000 marker. (B) Lane 6, 7, 8: infected cell focus
M: DL2000 marker. (C) Lane 10, 11, 12, 13: infected cell focus BHK-21-6,
tern Blot analysis of rMVA-mep infected BHK-21. M: Low molecular
tern blot of purified rMVA-mep infected BHK-21-6 (The sixth generation
21-16. Lane 4: BHK-21 cells.
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sixteenth generation of rMVA-mep-infected BHK-21
cells (Figure 3D, lane 2 and lane 3). No 17.9 kDa protein
was found in the negative control of BHK-21 cells
(Figure 3D, lane 4). These results demonstrated that the
MEP gene was successfully expressed in the rMVA-mep
with genetic stability and good immunogenicity.
Cellular immune responses
Cellular immune responses were evaluated by measuring
the production of IFN-γ and IL-4 by splenocytes from
mice at 35 dpi when stimulated by rMEP protein. As
shown in Figure 4A, IFN-γ and IL-4 productions from
mice received rMVA-mep (105TCID50, 10
6TCID50,
107TCID50), inactivated vaccine, EDIII, and rMEP were
significantly higher than that in the PBS and wild MVA
(P < 0.05). Mice immunized with rMVA-mep promoted
the IFN-γ and IL-4 levels in dose-dependent manner, inFigure 4 The cellular-mediated immune responses. (A) The cytokines. A
were collected to detect cytokine by ELISA. (B) spleen lymphocyte prolifera
bottomed microtiter plates and stimulated with rMEP for detecting the spl
mean± SD of three independent experiments. Statistically significant differewhich cytokines production of mice immunized with
107TCID50 rMVA-mep was observed highest among the
three dosages. Also, the levels of IFN-γ and IL-4 were
similar among mice immunized with rMVA-mep
(107TCID50), inactivated vaccine, EDIII, and rMEP.
These results suggested that rMVA-mep could induce
both Th1 and Th2 type immune response.
The level of lymphocyte proliferation varied among
the groups as shown in Figure 4B. The highest occurred
in the group immunized with inactivated vaccine of JEV
SA14-14-2, and this level was significantly higher than
those produced by PBS, wild MVA, or rMVA-mep
(105TCID50; 10
6TCID50). We also found that the level of
splenocyte proliferation observed from the groups
immunized with rMVA-mep (107TCID50), EDIII, and
rMEP was nearly equal; rMVA-mep can enhance
antigen-specific splenocyte proliferative response in a
dose-independent manner. No significantly lymphocytefter 2nd boost immunized 1 week, the sera from all experiment groups
tion response. The spleen lymphocytes were incubated in 96-well flat-
een lymphocyte proliferation response by MTT. The data are shown as
nces (P < 0.05) are indicated with different small letters.
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and wild MVA.
Anti-rMEP of JEV antibody titers and subtype analysis
To estimate the potential roles of rMVA-mep on the
humoral immune response, the IgG isotopes profiles of
sera from immunized mice at two weeks after three
immunizations were measured by ELISA method
(Figure 5). These results showed that mice immunized
with rMVA-mep generated a significant rMEP-specific
antibody response in dose-dependent manner, in which
mice injected with 107TCID50 rMVA-mep produced the
strongest antibody response among the three reachable
dosages (Figure 5A, IgG). Also, it was observed that the
level of IgG from mice given the inactivated vaccine,
EDIII and MEP were higher than that of mice given with
107TCID50 rMVA-mep. It was found that a combined
IgG1/2a response was characteristic of mice immunized
using an rMVA-mep prime-boost protocol (Figure 5B,
IgG1 and Figure 5C, IgG2a). Moreover, the antibody level
of IgG1 was significantly higher than that of IgG2a,
which indicated that the IgG1 antibody was the domin-
ant antibody subtype induced by rMVA-mep vaccination.
Low levels of both IgG1 and IgG2a were found in control
sera.
These results suggested that rMVA-mep might be as
potential candidate vaccine for the prevention of JEV
infection.
Neutralizing antibodies
Serum samples collected on days 14, 28 and 42 were
further evaluated for their ability to neutralize JEV
in vitro by the plaque reduction neutralization assay
(PRNT). As shown in Table 3 (2nd boost), although
neutralization titer of serum from mice immunized
with rMVA-mep (105TCID50 [20 ± 1.33] and 106
TCID50 [33 ± 2.33]) was significantly lower than that
of the mice immunized with JEV vaccine (58 ± 2.01),
EDIII (56 ± 1.99) and MEP (57 ± 1.99), rMVA-mep vac-
cination (107TCID50 [56 ± 1.01]) almostly produced the
equal level of neutralization antibody to that JEV vac-
cine, EDIII and MEP vaccinations. No JEV-neutralizing
antibodies were found in the PBS or wild MVA con-
trol group.
Mouse protection against JEV challenge
To investigate the development of protective immunity
further, all immunized mice were intraperitoneally chal-
lenged with a lethal dose (5 × 106pfu) of JEV SA14 at
two weeks after the final immunization. After the chal-
lenge, mice immunized with rMVA-mep (107TCID50),
EDIII, and rMEP or the inactivated vaccine showed
complete (100%) protection against JEV challenge, but
only one mouse (1/12) survived in the PBS controlgroup. Mice of the wild MVA group almost no survived
(Table 3).
Discussion
It was reported that the recombinant multi-epitope pep-
tide (rMEP) from JEV using epitope-based vaccine strat-
egies is capable of inducing remarkable humoral and
cellular immune responses and provided complete pro-
tection against lethal JEV challenge in mice [29]. Modi-
fied vaccinia virus Ankara (MVA) has been used to
develop recombinant vaccines against the vital diseases
including JEV, with some advantages, including contrib-
uting to replication-deficient virus efficiently replicates,
high bio-safety, high-level immunogenic heterologous
antigens expression. So it has been wildly used to de-
velop genetic engineering vaccines and gene therapy
[28]. In this paper, we investigated the potential immune
functions of the recombinant multi-epitope peptide
(rMEP) from JEV expressed in recombinant MVA as
multiple epitope vaccine.
The E protein of JEV is a major immunogenic antigen,
which shares various B-cell and T-cell epitopes [36].
Some studies have shown that fusion proteins containing
Th epitopes may enhance antibody production against
the B cell determinant [37], and the linking of a Th epi-
tope to a CTL determinant is effective in the generation
of antiviral CTLs [38]. Moreover, the Th cells activated
by a vaccine that contains CD4+ Th epitopes may se-
crete several CTL-inducing or antiviral cytokines, induce
CTL responses, and maintain CTL memory [39]. Ideally,
epitope-based vaccines should contain both B-cell and
T-cell epitopes (CTL epitopes, Th epitopes) that will
serve to induce humoral and cellular immune responses.
Therefore, in the present study, the selected epitopes
containing six B-cell epitopes {(75–92)–(149–163)–
(258–285)–(356–362)–(373–399)–(397–403)}, one CTL
epitope (60–68), and one Th epitope (436–445) from the
E protein of JEV [29] was constructed and generated the
recombinant virus (rMVA-mep), designated rMVA-mep.
In this paper, we obtained a recombinant MVA expres-
sing recombinant multi-epitope peptide (rMEP) from
JEV with genetic stability and good immunogenicity
(Figure 3D).
Balb/c mice are widely used experimental animal mod-
els. The immune epitopes and protection functions of
JEV are verified on Balb/c mice immunization experi-
ments [29]. Therefore, in this paper, we select the Balb/c
mice model to confirm the immune response of multiple
linear epitopes (B-cell, CTL and Th) of JEV expressed in
recombinant MVA. Although the results of Figures 4
and 5 showed no difference of IFN-γ, IL-4, IgG1, and
IgG2a titers among 107 TCID50 rMVA-mep, recombin-
ant ED3 and inactivated JE vaccine, it was also found
that live rMVA-mep elicited strongly immune responses
Figure 5 Specific antibody responses. The sera were collected on day 14 after prime, 1st boost and 2nd boost immunized for detecting the
antibody special to rMEP of JEV by ELISA, respectively. The data are shown as mean± SD of five mice and are fully representative for the
individual mice tested. (A) IgG antibody; (B) IgG1 antibody; (C) Ig2a antibody. Statistically significant differences (P< 0.05) are indicated with
different small letters.
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Table 3 The neutralizing antibody levels and protection
against JEV infection in immunized mice
Treatment PRNT50a Survival
rate (%)Prime 1st boost 2nd boost
rMVA-mep 105TCID50 <5 <8 20±1.33 60
c
106 TCID50 <7 9±1.33 33±2.33* 85
c
107 TCID50 <8 18±2.33* 56±1.01** 100
c
Inactivated JEV vaccine 9±1.33* 29±1.02** 58±2.01** 100c
EDIII 8±2.00* 28±1.99** 56±1.99** 100c
rMEP 9±1.01* 27±2.01** 57±1.99** 100c
Wild MVAb – – – 0
PBSb – – – 8.33
a Prime-boost-boost vaccinations (days 0, 14 and 28) with rMVA-mep were
carried out. On day 14 (prime), day 28 (first boost) and day 42 (second boost)
sera were taken and analyzed. 50% plaque reduction neutralizing titer
(PRNT50) was shown as the geometrical reciprocal of the sera dilution
resulting in a 50% reduction.
b No JEV-neutralizing antibodies were detectable in 1:2 diluted sera of the
mice in the PBS and wild MVA groups. n = 12, values represent the mean ±
standard error. Standard group is rMVA/M (105 TCID50).
* Significance [p< 0.05 to animals immunized with rMVA/M (105TCID50)].
**Significance [p<0.01 to animals immunized with rMVA/M (105TCID50)].
c Significance (p< 0.05 to 8.33%).
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immune responses was observed from the groups
immunized with 107 TCID50 rMVA-mep among the
experimental three concentrations. Our paper proved
that in the mouse model experiments, live rMVA-mep
could elicit strongly humoral and cellular immune
responses. Unexpectedly, expect for humoral immune
responses, recombinant ED3 and inactivated JE vaccine
also could induce cellular immune responses. Addition-
ally, the optimum concentration of live rMVA-mep to
trigger the maximum immune responses during the
immunization is unidentified, which need to be further
verified.
In this paper, it was found that mice immunized with
rMVA-mep produced the high level of the antibody pro-
duction with the major antibody subtype IgG1 and the
minor antibody subtype IgG2a. Our data showed that
rMVA-mep immunization could trigger the strongly
cytokine productions in which the levels of IFN-γ were
higher than that of IL-4. It has been reported that IgG1
is believed to indicate a humoral immune response,
whereas IgG2a is indicative of a cellular response [40].
Furthermore, cytokines play vital roles on various im-
mune responses. IFN-γ, the representative factor of Th1
type immune response, is produced by stimulated T cells
and has important immunomodulatory effects [41]. IL-4
can promote B-cell differentiation and enhance the pro-
duction of antibodies by sensitized B cells [42], which is
the representative factor of Th2 type immune response.
These results suggested that rMVA-mep could induce
both the humoral and cellular immune responses. It wasproved that the rMVA-mep vaccination produced strong
antibody response in dose-dependent manner, and a
mixed Th1/Th2 response in a mouse model.
These findings are consistent with previous studies that
rMEP could induce fine immune responses. Although
the levels of the neutralizing antibodies from mice immu-
nized with three concentrations of rMVA-mep were
lower than that of inactivated JEV vaccine, EDIII and
rMEP controls at the prime and 1st boost immunizations,
the level of the neutralizing antibodies from mice immu-
nized with 107TCID50 rMVA-mep was almost equal to
that of these controls at the 2nd boost immunization.
Also, the levels of the neutralizing antibodies from mice
immunized with three concentrations of rMVA-mep
were increased in dose-dependent manner. It was found
that the levels of the neutralizing antibodies from mice
immunized with three concentrations of rMVA-mep
were increased with three time immunization. Further-
more, it was observed that 107TCID50 rMVA-mep vac-
cination elicited high-level neutralizing antibody and
protection against JEV challenge. As for the duration of
neutralizing antibodies, it was required to be further
investigated. These results suggested that rMVA-mep
might be an attractive candidate vaccine for preventing
against JEV infection.
In conclusion, we first constructed the recombinant
viruses (rMVA-mep) expressing recombinant multi-
epitope peptide (rMEP) from JEV. It was demonstrated
that rMVA-mep vaccination can elicit both humoral and
cellular immune responses in a mouse model, such as
antibody and cytokines productions increase, and pro-
tection response against JEV challenge. These results
suggested recombinant MVA/M might be an attractive
candidate vaccine for JEV infection.
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